Clin Microbiol Infect by Aliabadi, N. et al.
Potential safety issues and other factors that may affect the 
introduction and uptake of rotavirus vaccines
N. Aliabadi*, J.E. Tate, and U.D. Parashar
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers 
for Disease Control and Prevention, Atlanta, GA, USA
Abstract
Rotavirus vaccines have demonstrated significant impact in reducing the burden of morbidity and 
mortality from childhood diarrhoea in countries that have implemented routine vaccination to date. 
Despite this success, in many countries, rotavirus vaccine coverage remains lower than that of 
other routine childhood vaccines. Several issues may potentially affect vaccine uptake, namely 
safety concerns related to intussusception with consequent age restrictions on rotavirus 
vaccination, contamination with porcine circovirus, vaccine-derived reassortant strains and 
hospitalization in newborn nurseries at time of administration of live oral rotavirus vaccine. In 
addition to these safety concerns, other factors may also affect uptake, including lower vaccine 
efficacy in the developing world, potential emergence of strains escaping from vaccine protection 
resulting in lower overall impact of a vaccination programme and sustainable vaccine financing. 
Although further work is needed to address some of these concerns, global policy bodies have 
reaffirmed that the benefits of rotavirus vaccination outweigh the risks, and vaccine use is 
recommended globally.
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Introduction
Rotavirus infection is a major contributor to severe childhood diarrhoea, causing significant 
morbidity and mortality, with nearly 200 000 deaths among children younger than 5 years of 
age attributable to rotavirus in 2011 [1–4]. The majority of rotavirus deaths occur in the 
developing world, with several countries in sub-Saharan Africa reporting rotavirus-specific 
death rates of over 100 per 100 000 children [4]. While mortality from rotavirus is 
uncommon in developed settings, the burden of severe morbidity is substantial. In the United 
States, before vaccine introduction, an estimated 55 000–70 000 hospital admissions for 
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severe rotavirus gastroenteritis occurred each year in children under 5 years of age, with 20 
to 60 deaths [5].
In 2006, two live, attenuated rotavirus (RV) vaccines, a pentavalent (RV5; RotaTeq; Merck 
and Co.) and a monovalent (RV1 Rotarix; GSK Biologicals) formulation, demonstrated 85–
98% efficacy against severe rotavirus gastroenteritis in large clinical trials conducted in the 
Americas and Europe [6,7]. These vaccines were subsequently recommended and licensed 
for routine use in the United States [5] and worldwide, with an emphasis on countries where 
mortality from diarrhoeal deaths was ≥10% among children under 5 years of age [8]. As of 
January 2016, these vaccines are being used in the national immunization programs of 80 
countries [9](http://sites.path.org/rotavirusvaccine/files/2015/12/PATH-Worldwide-
Rotavirus-Vaccine-Introduction-Map-EN-2016.01.01_WHO.jpg) (Fig. 1).
The burden of rotavirus has significantly decreased in many countries that have adopted 
routine rotavirus vaccination. Notably, reductions in diarrhoea deaths have been reported 
after rotavirus vaccine introduction in Brazil, Panama and Mexico [9]. In Brazil, rotavirus 
vaccine coverage reached 90% for the first dose of RV1 and 77% for the second dose among 
infants by 2008. That same year, the gastroenteritis mortality rate among children less than 1 
year of age decreased from 57 per 100 000 in 2004–2005 to 35 per 100 000, representing a 
relative reduction of 39% (95% confidence interval (CI), 29–49) [10]. In Mexico vaccine 
coverage reached 74% for the first dose of RV1 and 51% for the second dose among infants 
before the 2008 rotavirus season; during 2008, diarrhoea-associated mortality among infants 
11 months of age or younger declined by 41% (95% CI, 36–47) to 36 per 100 000 compared 
to 62 per 100 000 during the prevaccine years from 2003 to 2006 [11]; this reduction was 
sustained for 4 years [12,13]. Similarly, in Panama, where vaccine coverage reached 71% in 
2008, gastroenteritis-related mortality rate for children under 1 year of age decreased from 
73 deaths per 100 000 in the 2000–2005 prevaccine period to 40 per 100 000 in 2008, 
representing a 45% decrease [14]. In addition to these remarkable mortality benefits, 
reductions of 17–55% in hospitalizations for all-cause diarrhoea and of 49–92% in 
hospitalizations for rotavirus-specific diarrhoea have been reported in the United States, 
Europe, Australia, Latin America and Africa [9,15–17]. Since vaccine introduction in the 
United States in 2006, rotavirus seasons have been delayed in onset, of shorter duration and 
of diminished magnitude (Fig. 2) [18,19].
Despite the remarkable overall impact of rotavirus vaccination, vaccines have not been 
universally adopted around the world; notably, no country in Asia has adopted a routine 
nationwide rotavirus vaccination programme to date. In addition, in many countries that 
have adopted vaccination, coverage of rotavirus vaccines remains lower than that of other 
established childhood vaccines (http://www.who.int/mediacentre/factsheets/fs378/en/) [20]. 
Here we discuss some of the potential barriers that might be affecting uptake and use of 
rotavirus vaccines.
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Safety Concerns
Intussusception
Intussusception is a condition where one part of the intestine telescopes into an adjacent 
section, creating blockage and decreased circulation. If not corrected, it can lead to necrosis 
and perforation of the bowel and death. Mortality among young children hospitalized for 
intussusception is primarily related to suboptimal or delayed access to health care, and it 
ranges from as little as 0.1% in developed settings such as the United States and Europe to 
as high as 10–35% in some countries of Africa [21].
The first commercially available rotavirus vaccine, the rhesus rotavirus reassortant 
tetravalent vaccine (RRV-TV; Rotashield; Wyeth Vaccines), was introduced in 1998 in the 
US market and was recommended by the US Advisory Committee on Immunization 
Practices (ACIP) to be provided to all US infants as a three-dose schedule given at 2, 4 and 6 
months of age. Shortly after vaccine introduction, an increase in reports of intussusception 
among infants given RRV-TV was noted through the national Vaccine Adverse Event 
Reporting System [22]. This led to a temporary suspension of vaccine administration, and 
formal studies were launched to examine the association between RRV-TV and 
intussusception. Data from these studies confirmed an increased risk of intussusception with 
RRV-TV, with an almost 30-fold elevated risk of developing intussusception during the first 
3 to 7 days after the first dose of RRV-TV [23]. An expert group estimated that the 
population attributable risk of intussusception was ~1 excess case per 10 000 recipients of 
RRV-TV [24]. This level of risk was deemed unacceptable for further vaccine use; the ACIP 
withdrew its recommendation [25], and the manufacturer withdrew RRV-TV from the US 
market in 1999.
Both RV5 and RV1 have undergone close scrutiny for intussusception risk as a result of the 
RRV-TV experience. In large pre-licensure clinical trials which included over 60 000 
participants each, neither vaccine demonstrated an increased risk of intussusception [6,7]. 
The RV5 trial reported a relative risk of intussusception within 42 days after any of the three 
vaccine doses of 1.6 (95% CI, 0.4–6.4) [6] while the RV1 trial reported a relative risk of 0.85 
(95% CI, 0.3–2.42) for the period within 30 days of any of the two doses [7]. Given these 
reassuring data, the World Health Organization (WHO) recommended rotavirus vaccines for 
global use, noting that further postlicensure monitoring should continue to further examine 
any possible risk of intussusception.
Postlicensure studies have been conducted in Australia, Brazil, Mexico and the United States 
to specifically evaluate intussusception risk with use of either rotavirus vaccine [26]. Case 
series analyses from Australia, where both RV1 and RV5 are available, detected a low level 
risk in the first 21 days after dose 1 and the first 7 days after dose 2 for both vaccines, with 
an estimated excess of about 4.3 intussusception cases per 100 000 RV1-vaccinated infants 
and about 7 intussusception cases per 100 000 RV5-vaccinated recipients [27]. Data using 
both case series and case–control analyses showed an incidence ratio of 5.3 (95% CI, 3.0, 
9.3) and an odds ratio of 5.8 (95% CI, 2.6, 13.0), respectively, during 1 to 7 days after the 
first dose of RV1 in Mexico and an incidence ratio of 2.6 (95% CI, 1.3, 5.2) and an odds 
ratio of 1.9 (95% CI, 1.1, 3.4), respectively, in Brazil after the second RV1 dose [28]. These 
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risk figures translated into an excess of one to two cases of intussusception per 100 000 
vaccinated children. In the United States, one analysis of administrative data found that RV5 
was associated with 1.1 excess cases of intussusception per 100 000 recipients in the 7 days 
after the first dose and 1.5 cases of intussusception per 100 000 recipients in the 21 days 
after the first dose [29]. The same study noted an elevated risk after the second dose of RV1, 
but this analysis was underpowered. Another administrative database analysis of cohort data 
from six health care organizations found an increased risk of 5.3 cases of intussusception per 
100 000 vaccinated with RV1 [30].
Taken together, these data from various settings show an increased risk of intussusception 
with both RV5 and RV1, with about one to six excess cases per 100 000 vaccinated infants. 
The WHO and other policy bodies have reviewed these data in the context of the large health 
benefits of vaccination that have been seen in many countries, and they have reaffirmed the 
decision to recommend rotavirus vaccination, in view of the benefits greatly exceeding the 
risks.
Age restriction of rotavirus vaccine schedule
Naturally occurring intussusception is uncommon in the first 2 months of life, after which 
incidence increases rapidly to peak at 6 months of age and thereafter declines steadily [31]. 
With the withdrawn RRV-TV vaccine, for which catch-up vaccination was allowed up to 6 
months of age with the first dose, some data suggested that the risk of intussusception 
occurring after receipt of the first dose of vaccine was associated with older age at 
vaccination, with infants aged 90 days or older accounting for 80% of reported cases of 
intussusception although they only received 20% of vaccine doses [32]. Furthermore, no 
cases of intussusception were noted among infants vaccinated at less than 60 days of age. 
Although it is still debated whether the relative risk of intussusception differed according to 
the age at which the first vaccine dose was administered [33–35], the absolute risk would 
undoubtedly be greater at older ages, given the higher baseline rate of intussusception. Given 
these considerations, an upper age limit of 15 weeks for the first dose of RV5 and RV1 was 
recommended when they were introduced into national immunization programs [36].
In developed countries, the strict age restriction of 15 weeks for receipt of the first dose of 
rotavirus vaccination is estimated to reduce the coverage of rotavirus vaccine by 5–10% 
compared to other childhood vaccines based on data on timing of routine childhood 
vaccinations [37,38]. However, in developing countries, where delays in the timing of 
childhood vaccination are far more common, these age restrictions could substantially affect 
vaccine coverage by as much as 30–40% in some areas. A scenario analysis examined the 
benefits of rotavirus vaccination on mortality reduction from gastroenteritis versus the risk 
of fatal intussusception in 158 low- and middle-income countries when vaccine was 
provided in an age-restricted compared to an unrestricted schedule. This analysis found that 
lifting age restrictions would prevent 47 200 (18 700–63 700) more gastroenteritis deaths 
than an age-restricted schedule, while resulting in 294 (161–471) extra intussusception 
deaths [39]. Given these favorable benefit–risk data, in 2012 the WHO recommended that 
age restrictions on rotavirus vaccination in developing countries be relaxed, noting that 
vaccination should be as timely as possible to ensure maximum benefit [36]. Specifically, 
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while WHO still recommends that the first dose of rotavirus vaccine be given as soon as 
possible after 6 weeks of age, in settings where the mortality burden from rotavirus acute 
gastroenteritis is high, the 15-week age limit has been removed, and rotavirus vaccine is 
recommended to be administered orally alongside doses of diphtheria, pertussis and tetanus 
(DTP: DTP1 and DTP2 for RV1 and DTP1, DTP2 and DTP3 for RV5) with at least 4 weeks 
between doses, up to 24 months of age [40]. While several low-income countries have 
recommended rotavirus vaccination without age restriction per the 2012 WHO 
recommendations, others continue to adhere to the age restrictions. In addition, most high-
income countries still recommend vaccination with age restrictions [5,41].
Vulnerable populations
In a study using data from an active surveillance system, rotavirus vaccine coverage was 
compared to rotavirus prevalence rates in hospitalized children in an urban setting in the 
United States [42]. Researchers found that physician practices with lowest vaccine coverage 
(defined as <40%) had the highest prevalence of rotavirus. Of note, one of the low coverage 
locations was a neonatal intensive care unit (NICU). NICU patients may miss opportunities 
to receive rotavirus vaccine in the usual outpatient setting if they are hospitalized for 
prolonged periods to an age beyond 15 weeks, as they may become age ineligible to start the 
rotavirus vaccine series. Vaccination of these infants while they are still in the NICU has 
raised concerns about shedding and transmission of vaccine-derived virus to other infants in 
the NICU. Studies from the United States and Canada examining hospital administration of 
rotavirus vaccines for infants admitted in the NICU have shown that vaccine does not cause 
definite rotavirus-attributable symptomatology after vaccination; nor does it lead to 
increased rates of symptomatic nosocomial rotavirus after vaccination [43,44]. However, 
practices regarding rotavirus vaccination of infants while they are still in the NICU show 
substantial variation.
Porcine circovirus contamination
In 2010, contamination with porcine circovirus (PCV) was identified in both RV5 and RV1. 
PCV is a single-stranded DNA virus that infects pigs but has not been reported to cause 
disease in humans. RV1 was first found to contain full-length PCV1 genomes [45], and RV5 
was later found to contain PCV1 and PCV2 genome fragments [46]. The US Food and Drug 
Administration (FDA) temporarily suspended the use of RV1 in 2010 (http://www.fda.gov/
BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm205540). Data suggested that 
porcine trypsin, a reagent commonly used in the manufacture of biologicals (http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/
WC500162147.pdf), was likely the source of the detected PCV1 DNA [47]. After further 
review of data, an expert FDA advisory committee deemed it safe to resume use of RV1 and 
continue using RV5 (http://www.fda.gov/BiologicsBloodVaccines/Vaccines/
ApprovedProducts/ucm212140, http://www.who.int/immunization/newsroom/
news_rotavirus_vaccine_use/en/index.html), a position that was endorsed by the European 
regulatory agencies and the WHO.
Despite the recommendation to resume use of rotavirus vaccine, porcine circovirus 
contamination impacted vaccine integration into national immunization schedules. In France 
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and Spain introduction of vaccine was hindered because of these safety concerns (http://
venice.cineca.org/Venice2_WP3_Report_December2010.pdf) [48]. In Spain, although 
rotavirus vaccine had not been integrated, its use had been supported by the paediatric 
vaccine advisory committee since 2008, and coverage had reached 40% by 2010. Because of 
PCV1 contamination, the use of the vaccine was suspended for several months in 2010 in 
Spain, and the effects of this suspension on disease burden and healthcare-associated costs 
were examined [49]. It was estimated that in the 5 months of vaccine distribution 
suspension, assuming coverage had fallen to 0, 85 450 children were not vaccinated, 
resulting in an estimated 2904 episodes of gastroenteritis due to rotavirus, 497 
hospitalizations, 1444 emergency room visits, 1674 paediatrician visits and a total of €2.2 
million in avoidable costs.
Vaccine-derived strains associated with diarrhoea
Rotavirus vaccines contain live attenuated virus strains which replicate in the gastrointestinal 
tract after administration and have the potential to both shed via stool as well as being able 
to undergo reassortment with other vaccine strains or wild-type virus. Active acute 
gastrointestinal surveillance in the United States has identified both vaccine-derived strains 
and reassortant strains circulating in the community. One case report of horizontal 
transmission of vaccine virus documented the isolation of RV5-derived strains from a child 
evaluated in the emergency department whose only exposure to vaccine had been via a 
sibling who had recently been immunized with RV5 [50]. Another case series found that in 
106 rotavirus-positive stool specimens from patients with severe gastroenteritis, five were 
vaccine-reassortant or vaccine-derived strains [51]. Four of these were related to RV5 
vaccine, including three patients who had been recently vaccinated and were shedding either 
the RV5 vaccine strain or a double reassortant derived from two of the five rotavirus vaccine 
reassortant strains in RV5. The contribution of these identified strains to the patients' illness 
was not clear cut, as two were coinfected with other pathogens and two had prominent 
respiratory symptoms. An Australian study examined 61 children who had recently received 
RV5 and subsequently developed gastroenteritis [52]. Thirteen of these infants had vaccine-
derived rotavirus strains, and four of these demonstrated reassortment. These researchers 
also tested 460 faecal samples from the Australian severe gastroenteritis surveillance 
programs and found three vaccine-derived strains, two of which demonstrated reassortment. 
Finally, a case series from Finland also reported the presence of double-reassortant rotavirus 
in three symptomatic infants shortly after receiving RV5, as well as detection of vaccine 
strain in one infant [53]. Although these cases of severe gastroenteritis potentially related to 
vaccine-derived rotavirus strains are of concern, the overall incidence of such events appears 
to be small (estimated at 1 in 140 000 vaccinees in one study), and the risk is outweighed by 
the overwhelming positive impact of rotavirus vaccinations.
Other Factors
Lower vaccine efficacy in the developing world
Compared to the 85–98% vaccine efficacy against severe rotavirus gastroenteritis noted in 
key clinical trials in Latin America, the United States and Europe [6,7], studies from Africa 
and Asia have reported lower efficacy. In Africa a clinical trial of RV5 conducted in Ghana, 
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Kenya and Mali found an efficacy of 64% in the first year of life [54], while a trial of RV1 in 
South Africa and Malawi found an overall efficacy of 62% against severe rotavirus 
gastroenteritis in the first year of life [55]. In Asia RV5 was studied in Vietnam and 
Bangladesh and was found to be 51% efficacious [56]. Studies of RV1 in routine use in 
African settings have shown similar figures. When evaluated in routine programmatic use 
after licensure, RV1 was found to be 40–64% effective in South Africa and Malawi [57,58].
Reasons for lower effectiveness and efficacy compared to more developed settings are 
multifactorial, involving issues related to vaccine uptake and infants' ability to mount an 
immunoresponse. The presence of transplacental preexisting circulating antibody in the 
infant has been shown to decrease the infants' immunoresponse to vaccine [59,60]. Breast-
feeding was postulated to be one of the factors that may diminish immunoresponse to the 
vaccine based on in vitro studies [61], but a series of randomized clinical trials from South 
Africa, Pakistan and India did not show a difference in vaccine seroconversion among 
infants with unlimited breast-feeding compared to those whose breast-feeding was withheld 
around the time of vaccination [62–64]. Additionally, unsanitary living conditions, chronic 
malnutrition and the presence of coinfections also likely play a role in infants' 
immunoresponse to rotavirus vaccine, with a recent study from Bangladesh reporting 
rotavirus vaccine failing in 69% of infants who had received it as a result of a combination 
of these factors [65]. Finally, coadministration of rotavirus vaccine alongside oral poliovirus, 
while not having effect on the immunogenicity to oral poliovirus, has been shown to reduce 
the antibody response to rotavirus vaccine [66].
Despite the lower efficacy, however, the public health impact of vaccination will be 
substantial in low-income setting because of the tremendous burden of diarrhoeal disease. 
This is well illustrated by data from the rotavirus vaccine trial in South Africa and Malawi. 
In this trial, while vaccine efficacy was poorer in Malawi (49%) than in South Africa (77%), 
vaccination of 100 infants prevented 6.7 cases of severe rotavirus gastroenteritis in Malawi 
versus 4.2 in South Africa, the result of the higher baseline incidence in Malawi compared to 
South Africa. Indeed, it was this consideration of the large public health impact of 
vaccination that drove the WHO decision in 2009 to recommend rotavirus vaccination for all 
countries globally.
As these vaccines are increasingly in use in high-burden, developing countries, current 
research efforts are also underway to improve vaccine performance in these settings. Studies 
to determine the benefit of adding a third doses of RV1 are underway and have shown mixed 
results. A randomized controlled study in Ghana demonstrated that infants receiving a third 
dose of RV1 had increased seroconversion and mean titres of antirotavirus IgA compared to 
infants receiving the standard 2 doses [67], whereas a randomized study in Pakistan showed 
no such increase using the same dosing schedule [68]. In Bangladesh a 9-month booster 
dose of rotavirus vaccine, provided alongside the routine dose of measles–rubella vaccine, 
was shown to increase antirotavirus antibodies compared to infants who received measles–
rubella vaccine alone [69]. Further studies will help determine the utility of booster dosing. 
In addition to these studies, identifying more suitable markers as correlates of protection for 
rotavirus vaccines is also underway [70].
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Potential emergence of rotavirus strains escaping vaccine immunity
The rotavirus genome contains 11 RNA segments, two of which encode the outer capsid 
proteins VP7 and VP4 (G and P protein, respectively) and form the basis of binary 
classification (G and P type) of rotavirus [71]. Though reassortment among segments of the 
genome is common, before vaccine introduction, the majority of strains contained five 
combinations of G and P proteins: G1P [8], G2P [4], G3P [8], G4P [8] and G9P [8] [72,73]. 
The two rotavirus vaccine differ in composition; RV5 contains five bovine rotavirus strains 
that each express a human surface antigen of G1–4 and P1A [8] specificity, while RV1 
contains a single human-derived G1P [8] strain. Concern for selective pressure arose in some 
countries after vaccine implementation, particularly with observed dominance of G2P [4] 
strains in some settings with RV1 use—a strain with both different G and P type than the 
vaccine strain [74–77]. However, many of the strain changes observed in the initial years 
after vaccine implementation were not sustained over time [78] and thus may be related to 
natural secular variation rather than vaccine-induced selection pressure [79,80]. 
Furthermore, a recent meta-analysis that examined published genotype data from high- and 
middle-income countries using either or both RV1 and RV5 [81] found that both vaccines 
exerted similar effectiveness against a range of rotavirus strains, whether heterotypic or 
homotypic to the vaccine strain or strains, and no sustained dominance of a particular strain 
was seen. Although these data are reassuring, further surveillance is warranted, particularly 
in low-income settings, to further assess any emergence of strains not protected by vaccine.
Sustainable vaccine financing
Financing remains problematic in both developed and developing settings. In Europe, where 
rotavirus vaccination has not been adopted by all countries, a member-state survey in 2010 
identified at least two countries that had decided not to incorporate rotavirus vaccine into 
their immunization schedules, citing high vaccine cost as a factor (http://venice.cineca.org/
Venice2_WP3_Report_December2010.pdf). As an alternative, some groups have advocated 
for vaccinating high-risk infants only in these settings, to offset costs associated with 
universally immunizing all infants [82]. Government resources were used for acquiring 
vaccine in almost all of the early adopting Latin American countries, though insufficient 
funds were cited as posing constraints in some of these countries [83]. The Global Alliance 
for Vaccines and Immunization (GAVI) provides financial support for the introduction of 
rotavirus vaccine, providing subsidies for countries with average gross national income per 
capital over the last 3 years equal to or less than US$1580 and with WHO/UNICEF vaccine 
coverage estimates ≥70% (http://www.gavi.org/support/apply/). This has greatly facilitated 
vaccine introduction in eligible countries, with 37 countries having introduced rotavirus 
vaccine with support through GAVI as of January 2016 (Fig. 1) (http://sites.path.org/
rotavirusvaccine/files/2015/12/PATH-Worldwide-Rotavirus-Vaccine-Introduction-Map-
EN-2016.01.01_WHO.jpg). Several of these countries (e.g. Angola, Kenya) have entered 
GAVI's accelerated transition phase by 2016, where they will receive support to transition to 
fully financing their own immunization programme over the course of several years (http://
www.gavi.org/support/apply/graduating-countries/).
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Conclusions
The issues noted in this review highlight the need for ongoing surveillance and targeted 
research as rotavirus vaccines are increasingly introduced into national immunization 
programs and as GAVI-assisted countries transition to fully financing their own 
immunization programs (Table 1). Overall, the many examples of the positive impact of 
vaccination on morbidity and mortality from rotavirus diarrhoeal disease warrants continued 
use of these vaccines as these issues are addressed.
References
1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008 estimate of 
worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of 
universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect 
Dis. 2012; 12:136–41. [PubMed: 22030330] 
2. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused 
by rotavirus disease in children. Emerg Infect Dis. 2003; 9:565–72. [PubMed: 12737740] 
3. Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE, et al. Global causes 
of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One. 2013; 
8:e72788. [PubMed: 24023773] 
4. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. World Health Organization–Coordinated Global 
Rotavirus Surveillance Network. Global, regional, and national estimates of rotavirus mortality in 
children <5 years of age, 2000–2013. Clin Infect Dis. 2016; 62(Suppl 2):S96–105. [PubMed: 
27059362] 
5. Cortese MM, Parashar UD. Centers for Disease Control and Prevention. Prevention of rotavirus 
gastroenteritis among infants and children: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep. 2009; 58(RR-2):1–25.
6. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and 
efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006; 
354:23–33. [PubMed: 16394299] 
7. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and 
efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006; 
354:11–22. [PubMed: 16394298] 
8. Rotavirus vaccines: an update. Wkly Epidemiol Rec. 2009; 84:533–40. [PubMed: 20034143] 
9. Tate JE, Parashar UD. Rotavirus vaccines in routine use. Clin Infect Dis. 2014; 59:1291–301. 
[PubMed: 25048849] 
10. Lanzieri TM, Linhares AC, Costa I, Kolhe DA, Cunha MH, Ortega-Barria E, et al. Impact of 
rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis. 2011; 15:e206–
10. [PubMed: 21193339] 
11. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, 
Gomez-Altamirano CM, et al. Effect of rotavirus vaccination on death from childhood diarrhea in 
Mexico. N Engl J Med. 2010; 362:299–305. [PubMed: 20107215] 
12. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in 
Mexico. N Engl J Med. 2011; 365:772–3. [PubMed: 21864191] 
13. Gastanaduy PA, Sanchez-Uribe E, Esparza-Aguilar M, Desai R, Parashar UD, Patel M, et al. Effect 
of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. 
Pediatrics. 2013; 131:e1115–20. [PubMed: 23460689] 
14. Bayard V, DeAntonio R, Contreras R, Tinajero O, Castrejon MM, Ortega-Barria E, et al. Impact of 
rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in 
Panama. Int J Infect Dis. 2012; 16:e94–8. [PubMed: 22154592] 
15. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world impact of rotavirus 
vaccination. Pediatr Infect Dis J. 2011; 30(1 Suppl):S1–5. [PubMed: 21183833] 
Aliabadi et al. Page 9
Clin Microbiol Infect. Author manuscript; available in PMC 2018 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. Rha B, Tate JE, Payne DC, Cortese MM, Lopman BA, Curns AT, et al. Effectiveness and impact of 
rotavirus vaccines in the United States–2006–2012. Expert Rev Vaccines. 2014; 13:365–76. 
[PubMed: 24392657] 
17. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute 
gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis 
of hospital discharge data from 18 US states. J Infect Dis. 2010; 201:1617–24. [PubMed: 
20402596] 
18. Tate JE, Haynes A, Payne DC, Cortese MM, Lopman BA, Patel MM, et al. Trends in national 
rotavirus activity before and after introduction of rotavirus vaccine into the national immunization 
program in the United States, 2000 to 2012. Pediatr Infect Dis J. 2013; 32:741–4. [PubMed: 
23426425] 
19. Aliabadi N, Tate JE, Haynes AK, Parashar UD. Centers for Disease Control and Prevention. 
Sustained decrease in laboratory detection of rotavirus after implementation of routine 
vaccination-United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2015; 64:337–42. 
[PubMed: 25856253] 
20. Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M. National, state, and selected local 
area vaccination coverage among children aged 19–35 months–United States, 2014. MMWR Morb 
Mortal Wkly Rep. 2015; 64:889–96. [PubMed: 26313470] 
21. Jiang J, Jiang B, Parashar U, Nguyen T, Bines J, Patel MM. Childhood intussusception: a literature 
review. PLoS One. 2013; 8:e68482. [PubMed: 23894308] 
22. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus 
vaccine–United States, 1998–1999. MMWR Morb Mortal Wkly Rep. 1999; 48:577–81. [PubMed: 
10428095] 
23. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. 
Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001; 344:564–72. 
[PubMed: 11207352] 
24. Peter G, Myers MG. National Vaccine Advisory Committee, National Vaccine Program Office. 
Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics. 2002; 110:e67. 
[PubMed: 12456934] 
25. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. 
MMWR Morb Mortal Wkly Rep. 1999; 48:1007. [PubMed: 10577495] 
26. Buttery JP, Standish J, Bines JE. Intussusception and rotavirus vaccines: consensus on benefits 
outweighing recognized risk. Pediatr Infect Dis J. 2014; 33:772–3. [PubMed: 24732449] 
27. Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, et al. Intussusception risk and 
disease prevention associated with rotavirus vaccines in Australia’s National Immunization 
Program. Clin Infect Dis. 2013; 57:1427–34. [PubMed: 23964090] 
28. Patel MM, Lopez-Collada VR, Bulhoes MM, De Oliveira LH, Bautista Marquez A, Flannery B, et 
al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J 
Med. 2011; 364:2283–92. [PubMed: 21675888] 
29. Yih WK, Lieu TA, Kulldorff M, Martin D, McMahill-Walraven CN, Platt R, et al. Intussusception 
risk after rotavirus vaccination in US infants. N Engl J Med. 2014; 370:503–12. [PubMed: 
24422676] 
30. Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, et al. Risk of intussusception 
after monovalent rotavirus vaccination. N Engl J Med. 2014; 370:513–9. [PubMed: 24422678] 
31. Tai JH, Curns AT, Parashar UD, Bresee JS, Glass RI. Rotavirus vaccination and intussusception: 
can we decrease temporally associated background cases of intussusception by restricting the 
vaccination schedule? Pediatrics. 2006; 118:e258–64. [PubMed: 16882770] 
32. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on Rota-Shield and 
intussusception: the role of age at the time of vaccination. J Infect Dis. 2005; 192(Suppl 1):S36–
43. [PubMed: 16088803] 
33. Rothman KJ, Young-Xu Y, Arellano F. Age dependence of the relation between reassortant 
rotavirus vaccine (RotaShield) and intussusception. J Infect Dis. 2006; 193:898. [PubMed: 
16479526] 
Aliabadi et al. Page 10
Clin Microbiol Infect. Author manuscript; available in PMC 2018 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
34. Gargiullo PM, Murphy TV, Davis RL. Is there a safe age for vaccinating infants with tetravalent 
rhesus–human reassortant rotavirus vaccine? J Infect Dis. 2006; 194:1793–4. [PubMed: 17109356] 
35. Gargiullo PM, Murphy TV, Davis RL. Reply to Gargiullo et al. Is there a safe age for vaccinating 
infants with tetravalent rhesus–human reassortant rotavirus vaccine? J Infect Dis. 2006; 194:1794–
5.
36. Meeting of the Strategic Advisory Group of Experts on immunization, April 2012–conclusions and 
recommendations. Wkly Epidemiol Rec. 2012; 87:201–16. [PubMed: 24340402] 
37. Hull BP, Menzies R, Macartney K, McIntyre PB. Impact of the introduction of rotavirus vaccine on 
the timeliness of other scheduled vaccines: the Australian experience. Vaccine. 2013; 31:1964–9. 
[PubMed: 23422140] 
38. Parashar UD, Alexander JP, Glass RI. Advisory Committee on Immunization Practices (ACIP), 
Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among 
infants and children. Recommendations of the Advisory Committee on Immunization Practices 
(ACIP). MMWR Recomm Rep. 2006; 55(RR-12):1–13.
39. Patel MM, Clark AD, Sanderson CF, Tate J, Parashar UD. Removing the age restrictions for 
rotavirus vaccination: a benefit–risk modeling analysis. PLoS Med. 2012; 9:e1001330. [PubMed: 
23109915] 
40. Rotavirus vaccines. WHO position paper–January 2013. Wkly Epidemiol Rec. 2013; 88:49–64. 
[PubMed: 23424730] 
41. Vesikari T, Van Damme P, Giaquinto C, Dagan R, Guarino A, Szajewska H, et al. European 
Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in 
Europe: update 2014. Pediatr Infect Dis J. 2015; 34:635–43. [PubMed: 25860532] 
42. Sahni LC, Tate JE, Payne DC, Parashar UD, Boom JA. Variation in rotavirus vaccine coverage by 
provider location and subsequent disease burden. Pediatrics. 2015; 135:e432–9. [PubMed: 
25583918] 
43. Monk HM, Motsney AJ, Wade KC. Safety of rotavirus vaccine in the NICU. Pediatrics. 2014; 
133:e1555–60. [PubMed: 24843056] 
44. Thrall S, Doll MK, Nhan C, Gonzales M, Perreault T, Lamer P, et al. Evaluation of pentavalent 
rotavirus vaccination in neonatal intensive care units. Vaccine. 2015; 33:5095–102. [PubMed: 
26296493] 
45. Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, et al. Viral nucleic acids in 
live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010; 
84:6033–40. [PubMed: 20375174] 
46. McClenahan SD, Krause PR, Uhlenhaut C. Molecular and infectivity studies of porcine circovirus 
in vaccines. Vaccine. 2011; 29:4745–53. [PubMed: 21569811] 
47. Dubin G, Toussaint JF, Cassart JP, Howe B, Boyce D, Friedland L, et al. Investigation of a 
regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human 
rotavirus vaccine, Rotarix: approach and outcome. Hum Vaccin Immunother. 2013; 9:2398–408. 
[PubMed: 24056737] 
48. Parez N, Giaquinto C, Du Roure C, Martinon-Torres F, Spoulou V, Van Damme P, et al. Rotavirus 
vaccination in Europe: drivers and barriers. Lancet Infect Dis. 2014; 14:416–25. [PubMed: 
24758998] 
49. Bouzon Alejandro M, Diez Domingo J, Martinon-Torres F. Circovirus and impact of temporary 
withdrawal of rotavirus vaccines in Spain. Hum Vaccin. 2011; 7:798–9. [PubMed: 21715979] 
50. Payne DC, Edwards KM, Bowen MD, Keckley E, Peters J, Esona MD, et al. Sibling transmission 
of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics. 2010; 
125:e438–41. [PubMed: 20100758] 
51. Boom JA, Sahni LC, Payne DC, Gautam R, Lyde F, Mijatovic-Rustempasic S, et al. Symptomatic 
infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case 
series. J Infect Dis. 2012; 206:1275–9. [PubMed: 22872730] 
52. Donato CM, Ch’ng LS, Boniface KF, Crawford NW, Buttery JP, Lyon M, et al. Identification of 
strains of RotaTeq rotavirus vaccine in infants with gastro-enteritis following routine vaccination. J 
Infect Dis. 2012; 206:377–83. [PubMed: 22615314] 
Aliabadi et al. Page 11
Clin Microbiol Infect. Author manuscript; available in PMC 2018 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
53. Hemming M, Vesikari T. Vaccine-derived human-bovine double reassortant rotavirus in infants 
with acute gastroenteritis. Pediatr Infect Dis J. 2012; 31:992–4. [PubMed: 22581224] 
54. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent 
rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-
Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376(9741):
606–14. [PubMed: 20692030] 
55. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus 
vaccine on severe diarrhea in African infants. N Engl J Med. 2010; 362:289–98. [PubMed: 
20107214] 
56. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, et al. Efficacy of pentavalent 
rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: 
a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376(9741):615–23. [PubMed: 
20692031] 
57. Groome MJ, Page N, Cortese MM, Moyes J, Zar HJ, Kapongo CN, et al. Effectiveness of 
monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in 
South African children: a case–control study. Lancet Infect Dis. 2014; 14:1096–104. [PubMed: 
25303843] 
58. Bar-Zeev N, Kapanda L, Tate JE, Jere KC, Iturriza-Gomara M, Nakagomi O, et al. Effectiveness of 
a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational 
and case–control study. Lancet Infect Dis. 2015; 15:422–8. [PubMed: 25638521] 
59. Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, et al. Maternal 
antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? 
Vaccine. 2011; 29:1242–7. [PubMed: 21147127] 
60. Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, et al. 
Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine 
ORV-116E in Indian infants. Vaccine. 2014; 32:651–6. [PubMed: 24374502] 
61. Moon SS, Wang Y, Shane AL, Nguyen T, Ray P, Dennehy P, et al. Inhibitory effect of breast milk 
on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J. 2010; 29:919–23. [PubMed: 
20442687] 
62. Groome MJ, Moon SS, Velasquez D, Jones S, Koen A, van Niekerk N, et al. Effect of 
breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized 
trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ. 2014; 92:238–
45. [PubMed: 24700991] 
63. Rongsen-Chandola T, Strand TA, Goyal N, Flem E, Rathore SS, Arya A, et al. Effect of 
withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian 
infants. Vaccine. 2014; 32(Suppl 1):A134–9. [PubMed: 25091668] 
64. Ali A, Kazi AM, Cortese MM, Fleming JA, Moon S, Parashar UD, et al. Impact of withholding 
breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine–a 
randomized trial. PLoS One. 2015; 10:e0127622. [PubMed: 26035743] 
65. Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, et al. Environmental enteropathy, 
oral vaccine failure and growth faltering in infants in Bangladesh. EBioMedicine. 2015; 2:1759–
66. [PubMed: 26870801] 
66. Patel M, Steele AD, Parashar UD. Influence of oral polio vaccines on performance of the 
monovalent and pentavalent rotavirus vaccines. Vaccine. 2012; 30(Suppl 1):A30–5. [PubMed: 
22520134] 
67. Armah G, Lewis KD, Cortese MM, Parashar UD, Ansah A, Gazley L, et al. A randomized 
controlled trial of the impact of alternative dosing schedules on the immune response to human 
rotavirus vaccine in rural Ghanaian infants. J Infect Dis. 2016 Jun 1; 213(11):1678–85. [PubMed: 
26823335] 
68. Ali SA, Kazi AM, Cortese MM, Fleming JA, Parashar UD, Jiang B, et al. Impact of different 
dosing schedules on the immunogenicity of the human rotavirus vaccine in infants in Pakistan: a 
randomized trial. J Infect Dis. 2014; 210:1772–9. [PubMed: 24939906] 
Aliabadi et al. Page 12
Clin Microbiol Infect. Author manuscript; available in PMC 2018 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
69. Zaman K, Fleming JA, Victor JC, Yunus M, Bari TI, Azim T, et al. Non-interference of rotavirus 
vaccine with measles–rubella vaccine at 9 months and improvements in anti-rotavirus immunity: a 
randomized trial. J Infect Dis. 2016 Jun 1; 213(11):1686–93. [PubMed: 26823338] 
70. Angel J, Steele AD, Franco MA. Correlates of protection for rotavirus vaccines: possible 
alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother. 2014; 
10:3659–71. [PubMed: 25483685] 
71. Estes MK, Cohen J. Rotavirus gene structure and function. Microbiol Rev. 1989; 53:410–49. 
[PubMed: 2556635] 
72. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype 
diversity and reassortment between human and animal rotavirus strains: implications for rotavirus 
vaccine programs. J Infect Dis. 2005; 192(Suppl 1):S146–59. [PubMed: 16088798] 
73. Banyai K, Laszlo B, Duque J, Steele AD, Nelson EA, Gentsch JR, et al. Systematic review of 
regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: 
insights for understanding the impact of rota-virus vaccination programs. Vaccine. 2012; 30(Suppl 
1):A122–30. [PubMed: 22520121] 
74. Hull JJ, Teel EN, Kerin TK, Freeman MM, Esona MD, Gentsch JR, et al. United States rotavirus 
strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. 
Pediatr Infect Dis J. 2011; 30(1 Suppl):S42–7. [PubMed: 21183839] 
75. Carvalho-Costa FA, Volotao Ede M, de Assis RM, Fialho AM, da de Andrade JS, Rocha LN, et al. 
Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 
2005–2009. Pediatr Infect Dis J. 2011; 30(1 Suppl):S35–41. [PubMed: 21048523] 
76. Kirkwood CD, Boniface K, Barnes GL, Bishop RF. Distribution of rotavirus genotypes after 
introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization 
Program of Australia. Pediatr Infect Dis J. 2011; 30(1 Suppl):S48–53. [PubMed: 21183840] 
77. Nakagomi T, Cuevas LE, Gurgel RG, Elrokhsi SH, Belkhir YA, Abugalia M, et al. Apparent 
extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of 
rotavirus vaccine. Arch Virol. 2008; 153:591–3. [PubMed: 18175037] 
78. Gurgel RQ, de Alvarez AJ, Rodrigues A, Ribeiro RR, Dolabella SS, Da Mota NL, et al. Incidence 
of rotavirus and circulating genotypes in Northeast Brazil during 7 years of national rotavirus 
vaccination. PLoS One. 2014; 9:e110217. [PubMed: 25360784] 
79. Guerra SF, Linhares AC, Mascarenhas JD, Oliveira A, Justino MC, Soares LS, et al. Rotavirus 
strain surveillance for three years following the introduction of rotavirus vaccine into Belem, 
Brazil. J Med Virol. 2015; 87:1303–10. [PubMed: 25879653] 
80. Patel MM, de Oliveira LH, Bispo AM, Gentsch J, Parashar UD. Rotavirus P[4]G2 in a vaccinated 
population, Brazil. Emerg Infect Dis. 2008; 14:863–5. [PubMed: 18439390] 
81. Leshem E, Lopman B, Glass R, Gentsch J, Banyai K, Parashar U, et al. Distribution of rotavirus 
strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic 
review and meta-analysis. Lancet Infect Dis. 2014; 14:847–56. [PubMed: 25082561] 
82. Bruijning-Verhagen P, Mangen MJ, Felderhof M, Hartwig NG, van Houten M, Winkel L, et al. 
Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative 
to universal vaccination. BMC Med. 2013; 11:112. [PubMed: 23622110] 
83. de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in 
the Americas: progress and lessons learned. Expert Rev Vaccines. 2008; 7:345–53. [PubMed: 
18393604] 
84. Bruijning-Verhagen P, Mangen MJ, Felderhof M, Hartwig NG, van Houten M, Winkel L, et al. 
Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative 
to universal vaccination. BMC Med. 2013; 11:112. [PubMed: 23622110] 
85. de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in 
the Americas: progress and lessons learned. Expert Rev Vaccines. 2008; 7:345–53. [PubMed: 
18393604] 
86. GAVI. [accessed February 2016] http://www.gavi.org/support/apply/
87. GAVI. [accessed February 2016] http://www.gavi.org/support/apply/graduating-countries/
Aliabadi et al. Page 13
Clin Microbiol Infect. Author manuscript; available in PMC 2018 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Rotavirus introduction worldwide, PATH, as of January 2016.
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Fig. 2. 
Total and positive rotavirus tests, National Respiratory and Enteric Virus Surveillance 
System data, United States, 2000–2014 [19].
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Table 1
Factors influencing uptake of rotavirus vaccines
Concern Issue Major findings Reference
Safety Intussusception • 1–6 excess 
cases/100 000 
recipients.
• Vaccine benefits 
outweigh risks.
[21–30]
Age restriction of 15 
weeks (dose 1) in 
vaccine schedule
• Risk of 
intussusception 
may be related 
to older age at 
vaccination.
• Restriction may 
reduce vaccine 
coverage 5–10% 
in developed but 
as much as 30–
40% in some 
developing 
countries.
• Lifting 
restriction could 
potentially 
prevent 47 200 
AGE deaths 
while causing an 
additional 294 
intussusception 
deaths.
• In view of the 
benefits 
exceeding risks 
in high AGE 
mortality 
settings, the 
upper limit of 
15 weeks on 
dose 1 was 
relaxed by 
WHO, and 
vaccination is 
allowed 
concurrently 
with other 
childhood 
vaccines up to 
24 months of 
age.
[31–41]
NICU patients • NICU patients 
may miss 
opportunity to 
receive vaccine 
because they 
may be age 
ineligible by 
discharge.
• No definite 
attributable risk 
of AGE after 
vaccination of 
infants in NICU 
documented.
[42–44]
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Concern Issue Major findings Reference
Porcine circovirus • 2010 RV1/RV5 
found with PCV 
contamination, 
leading to a 
suspension of 
RV1 vaccination 
for short period.
• After thorough 
review, FDA 
panel found no 
evidence of risk 
from 
vaccination and 
deemed it safe 
to resume.
[45–49], http://www.fda.gov/BiologicsBloodVaccines/Vaccines/
ApprovedProducts/ucm205540, http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2014/02/WC500162147.pdf, http://
www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
ucm212140, http://www.who.int/immunization/newsroom/
news_rotavirus_vaccine_use/en/index.html, http://venice.cineca.org/
Venice2_WP3_Report_December2010.pdf
Vaccine-derived strains • ~1/140 000 RV5 
vaccinees have 
vaccine-derived 
rotavirus strain 
that could cause 
severe rotavirus 
disease.
• Risk 
outweighed by 
the large health 
benefits of 
rotavirus 
vaccination.
[50–52]
Other Lower efficacy in 
developing countries
• Modest vaccine 
efficacy of 40–
64% in 
developing 
countries still 
demonstrates 
impact in 
higher-burden 
settings.
• Presence of 
transplacental 
maternal 
antibodies, 
chronic 
malnutrition, 
coinfections, 
coadministration 
with oral 
poliovirus, may 
contribute to 
decreased 
vaccine 
effectiveness in 
developing 
world.
• Breast-feeding 
not shown to be 
a factor linked 
with lower 
vaccine uptake.
• Vaccine 
schedules with 
additional 
dosing 
underway to 
determine if 
boosting 
improves 
[54–70]
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Concern Issue Major findings Reference
vaccine 
effectiveness.
Emergence of strains 
escaping vaccine 
immunity
• RV1/RV5 show 
similar 
effectiveness to 
heterotypic/
homotypic 
strains.
• No sustained 
dominance of 
any strain since 
vaccine 
introduction.
• Further 
surveillance is 
warranted.
[74–81]
Financing • Some developed 
countries cite 
low burden and 
high cost as 
barrier to 
universal 
introduction.
• GAVI 
subsidizes 
eligible 
countries, 37 to 
date have 
introduced 
rotavirus 
vaccine.
• As countries 
transition out of 
GAVI 
assistance, 
evaluation of 
sustainability of 
vaccine 
programs 
needed.
[84–87], http://venice.cineca.org/Venice2_WP3_Report_December2010.pdf
AGE, acute gastroenteritis; FDA, US Food and Drug Administration; GAVI, Global Alliance for Vaccines and Immunization; NICU, neonatal 
intensive care unit; PCV, porcine circovirus; RV, rotavirus; WHO, World Health Organization
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